logo

For the Inventor, By the Inventor

Stevenage, United Kingdom

Henry Anderson Kelly

This inventor holds 13 USPTO granted patents. Top assignees: Glaxo Group Limited, Smithkline Beecham Corporation. Active years: 2002-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Henry Anderson Kelly. Retrieved from https://idiyas.com/inventor/henry-anderson-kelly

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Standon, GB (2002 - 2003)
  • Stevenage, GB (2006 - 2010)

Company Filing History:

goldMedal8 out of 1,169 
 
Glaxo Group Limited
 patents
silverMedal5 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 2002-2010

Loading Chart...
13 patents (USPTO):Explore Patents
1. 7645338 - Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide (2010-01-12),
2. 7517879 - Pyrrolidine derivatives as factor Xa inhibitors (2009-04-14),
3. 7482374 - Pyrrolidine-2-ones as Factor Xa inhibitors (2009-01-27),
4. 7429587 - Pyrrolidine derivatives as factor Xa inhibitors (2008-09-30),
5. 7329685 - 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases (2008-02-12),
6. 7326785 - Pyrrolidine derivatives as factor XA inhibitors (2008-02-05),
7. 7282497 - Pyrrolidin-2-one derivatives as inhibitors of factor xa (2007-10-16),
8. 7226929 - Pyrrolidin-2-one derivatives as inhibitors of factor xa (2007-06-05),
9. 7186717 - Pyrrolidine derivatives as Factor Xa inhibitors (2007-03-06),
10. 7179835 - 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors (2007-02-20),
11. 7084139 - Pyrrolidin-2-one derivatives as inhibitors of factor Xa (2006-08-01),
12. 6670381 - Benzamide derivatives as thrombin inhibitors (2003-12-30),
13. 6441008 - Benzamide derivatives as thrombin inhibitors (2002-08-27),

Title: Henry Anderson Kelly: Innovator in Pharmaceutical Chemistry

Introduction

Henry Anderson Kelly is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 13 patents. His work primarily focuses on the development of innovative compounds that serve as Factor Xa inhibitors, which are crucial in the treatment of various clinical conditions.

Latest Patents

Among his latest patents, one includes the invention of crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide. This invention encompasses the compound in a substantially crystalline form, along with pharmaceutical formulations, processes for its preparation, and its medical applications. Another significant patent involves pyrrolidine derivatives as Factor Xa inhibitors, detailing the compounds' formula, preparation processes, and their use in medicine.

Career Highlights

Henry has worked with prominent companies in the pharmaceutical industry, including Glaxo Group Limited and SmithKline Beecham Corporation. His experience in these organizations has allowed him to contribute to groundbreaking research and development in drug formulation and therapeutic applications.

Collaborations

Henry has collaborated with esteemed colleagues such as Nigel Stephen Watson and Robert John Young. Their combined expertise has further advanced the field of pharmaceutical innovations.

Conclusion

Henry Anderson Kelly's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to impact the development of effective medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…